AstraZeneca Q3 2026: EPS More Than Doubles Wall Street's Estimate
As seen on the 24/7 Wall St. homepage on October 30, 2026.
Oncology revenue rose 17%, more than absorbing a 25% drop in Farxiga after US generics arrived, and AstraZeneca still beat EPS expectations. Management reaffirmed full-year guidance and pointed to 2027 readouts.
Continue ReadingShow less
AstraZeneca reported adjusted EPS of $2.79 for Q3 2026, beating expectations for the sixth consecutive quarter by the widest margin in recent memory.
Oncology grew 17%, led by Enhertu, Imfinzi and Tagrisso, more than absorbing a 25% decline in Farxiga after U.S. generics entered the market. Total revenue of $16.21 billion topped expectations.
Core operating margin widened three percentage points to 36% as the mix shifted toward higher-margin oncology products.
Sponsored
Management reaffirmed full-year 2026 guidance and signaled it intends to raise the annual dividend to $3.30 per share. CEO Pascal Soriot pointed to 2027 pipeline readouts with peak revenue potential above $20 billion.
FY and Q4 2026 results arrive February 9, 2027, the next checkpoint on whether the oncology engine justifies this quarter's trajectory.